Title:
SPARC-DERIVED CANCER REJECTION ANTIGEN PEPTIDE AND PHARMACEUTICAL COMPRISING THE SAME
Document Type and Number:
WIPO Patent Application WO/2007/145318
Kind Code:
A1
Abstract:
The object is to identify a peptide derived from SPARC protein which can induce a human cytotoxic (killer) T cell and a helper T cell both reactive to a tumor, and to provide a means for enabling a tumor immunotherapy in a cancer patient having a high level of SPARC expression. Disclosed is a peptide (A) or (B): (A) a peptide which comprises an amino acid sequence depicted in any one of SEQ ID NOs:1-3; and (B) a peptide which comprises an amino acid sequence having the substitution or addition of one or several amino acid residues in a peptide comprising an amino acid sequence depicted in any one of SEQ ID NOs:1-3 and which can induce a killer T cell.
Inventors:
NISHIMURA YASUHARU (JP)
IKUTA YOSHIAKI (JP)
NAKATSURU SHUICHI (JP)
IKUTA YOSHIAKI (JP)
NAKATSURU SHUICHI (JP)
Application Number:
PCT/JP2007/062117
Publication Date:
December 21, 2007
Filing Date:
June 15, 2007
Export Citation:
Assignee:
UNIV KUMAMOTO (JP)
ONCO THERAPY SCIENCE INC (JP)
NISHIMURA YASUHARU (JP)
IKUTA YOSHIAKI (JP)
NAKATSURU SHUICHI (JP)
ONCO THERAPY SCIENCE INC (JP)
NISHIMURA YASUHARU (JP)
IKUTA YOSHIAKI (JP)
NAKATSURU SHUICHI (JP)
International Classes:
C07K14/47; A61K38/00; A61K39/00; A61P35/00; C07K16/18; C12N5/07; C12N5/078; C12N5/0783; C12N5/09
Domestic Patent References:
| WO2006043362A1 | 2006-04-27 |
Foreign References:
| JP2006503575A | 2006-02-02 | |||
| JP2004303688A | 2004-10-28 |
Other References:
NAKATSURA T. ET AL.: "Mouse Homologue of a Novel Huma Oncofetal Antigen Glypican-3, Evokes T-Cell-Mediated Tumor Rejection without Autoimmune Reactions in Mice", CLIN. CANCER RES., vol. 10, no. 24, 2004, pages 8630 - 8640, XP003016234
WANG C.S. ET AL.: "Overexpression of SPARC Gene in Human Gastric Carcinoma and Its Clinic-Pathologic Significance", BR. J. CANCER, vol. 91, no. 11, 2004, pages 1924 - 1930, XP003020536
IKUTA Y. ET AL.: "Highly Sensitive Detection of Melanoma at an Early Stage Based on the Increased Serum Secreated Protein Acidic and Rich in Cysteine and Glypican-3 Levels", CLIN. CANCER RES., vol. 11, no. 22, 2005, pages 8079 - 8088, XP002456096
KOMORI H. ET AL.: "Identification of HLA-A2- or HLA-A24-Restricted CTL Epitopes Possibly Useful for Glypican-3-Specific Immunotherapy of Hepatocellular Carcinoma", CLIN. CANCER RES., vol. 12, no. 9, 2006, pages 2689 - 2697, XP003020537
AKIYAMA Y. ET AL.: "Identification, of HLA-A24-Restricted CTL Epitope Encoded by the Matrix Protein pp65 of Human Cytomegalovirus", IMMUNOL. LETT., vol. 83, no. 1, 2002, pages 21 - 30, XP003020538
IKUTA Y. ET AL.: "Gan Kogen SPARC o Mochiita Gan Men'eki Ryoho Model no Kakuritsu", DAI 10 KAI SOCIETY FOR FUNDAMENTAL CANCER IMMUNOLOGY SOKAI SHOROKU, 30 June 2006 (2006-06-30), pages 58, XP003020539
IKUTA Y. ET AL.: "Gan Tokuiteki ni Kohatsugen suru SPARC o Hyoteki to shita Mouse Gan Men'eki Ryoho Model no Kochiku", DAI 65 KAI MANNAUL MEETING OF THE JAPAN CANCER ASSOCIATION KIJI, 28 August 2006 (2006-08-28), pages 62 + ABSTR. NO. 0-147, XP003020540
CLINICAL CANCER RESEARCH, vol. 11, 2005, pages 8079 - 8088
"Molecular Cloning", 1989, COLD SPRING HARBOR LABORATORY, article "Molecular Cloning: A laboratory Manual"
"Current Protocols in Molecular Biology", 1987, JOHN WILEY & SONS, pages: 1 - 38
CURRENT PROTOCOLS IN MOLECULAR BIOLOGY
G KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
NATURE, vol. 344, 1990, pages 873
J. IMMUNOL., vol. 148, 1992, pages 1438
NAKATSURA,T ET AL., CLIN CANCER RES, vol. 10, 2004, pages 8630 - 8640
See also references of EP 2030984A4
WANG C.S. ET AL.: "Overexpression of SPARC Gene in Human Gastric Carcinoma and Its Clinic-Pathologic Significance", BR. J. CANCER, vol. 91, no. 11, 2004, pages 1924 - 1930, XP003020536
IKUTA Y. ET AL.: "Highly Sensitive Detection of Melanoma at an Early Stage Based on the Increased Serum Secreated Protein Acidic and Rich in Cysteine and Glypican-3 Levels", CLIN. CANCER RES., vol. 11, no. 22, 2005, pages 8079 - 8088, XP002456096
KOMORI H. ET AL.: "Identification of HLA-A2- or HLA-A24-Restricted CTL Epitopes Possibly Useful for Glypican-3-Specific Immunotherapy of Hepatocellular Carcinoma", CLIN. CANCER RES., vol. 12, no. 9, 2006, pages 2689 - 2697, XP003020537
AKIYAMA Y. ET AL.: "Identification, of HLA-A24-Restricted CTL Epitope Encoded by the Matrix Protein pp65 of Human Cytomegalovirus", IMMUNOL. LETT., vol. 83, no. 1, 2002, pages 21 - 30, XP003020538
IKUTA Y. ET AL.: "Gan Kogen SPARC o Mochiita Gan Men'eki Ryoho Model no Kakuritsu", DAI 10 KAI SOCIETY FOR FUNDAMENTAL CANCER IMMUNOLOGY SOKAI SHOROKU, 30 June 2006 (2006-06-30), pages 58, XP003020539
IKUTA Y. ET AL.: "Gan Tokuiteki ni Kohatsugen suru SPARC o Hyoteki to shita Mouse Gan Men'eki Ryoho Model no Kochiku", DAI 65 KAI MANNAUL MEETING OF THE JAPAN CANCER ASSOCIATION KIJI, 28 August 2006 (2006-08-28), pages 62 + ABSTR. NO. 0-147, XP003020540
CLINICAL CANCER RESEARCH, vol. 11, 2005, pages 8079 - 8088
"Molecular Cloning", 1989, COLD SPRING HARBOR LABORATORY, article "Molecular Cloning: A laboratory Manual"
"Current Protocols in Molecular Biology", 1987, JOHN WILEY & SONS, pages: 1 - 38
CURRENT PROTOCOLS IN MOLECULAR BIOLOGY
G KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
NATURE, vol. 344, 1990, pages 873
J. IMMUNOL., vol. 148, 1992, pages 1438
NAKATSURA,T ET AL., CLIN CANCER RES, vol. 10, 2004, pages 8630 - 8640
See also references of EP 2030984A4
Attorney, Agent or Firm:
SIKs & Co. (Kyobashi-Nisshoku Bldg.8-7, Kyobashi 1-chom, Chuo-ku Tokyo 31, JP)
Download PDF:
Previous Patent: VALVE DEVICE AND DEVICE FOR CONTROLLING IDLE AIR AMOUNT
Next Patent: PROCESSOR AND COMMAND CONTROL METHOD
Next Patent: PROCESSOR AND COMMAND CONTROL METHOD